Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Marie-Jeanne Buscot, Costan G Magnussen
No abstract text is available yet for this article.
May 18, 2019: European Heart Journal
#2
Claire E Raphael, Michael Frenneaux
No abstract text is available yet for this article.
May 18, 2019: European Heart Journal
#3
Laura N Anderson, Sarah Carsley, Brendan T Smith
No abstract text is available yet for this article.
May 18, 2019: European Heart Journal
#4
Ioanna Tzoulaki, Raphaële Castagné, Claire L Boulangé, Ibrahim Karaman, Elena Chekmeneva, Evangelos Evangelou, Timothy M D Ebbels, Manuja R Kaluarachchi, Marc Chadeau-Hyam, David Mosen, Abbas Dehghan, Alireza Moayyeri, Diana L Santos Ferreira, Xiuqing Guo, Jerome I Rotter, Kent D Taylor, Maryam Kavousi, Paul S de Vries, Benjamin Lehne, Marie Loh, Albert Hofman, Jeremy K Nicholson, John Chambers, Christian Gieger, Elaine Holmes, Russell Tracy, Jaspal Kooner, Philip Greenland, Oscar H Franco, David Herrington, John C Lindon, Paul Elliott
AIMS: To characterize serum metabolic signatures associated with atherosclerosis in the coronary or carotid arteries and subsequently their association with incident cardiovascular disease (CVD). METHODS AND RESULTS: We used untargeted one-dimensional (1D) serum metabolic profiling by proton nuclear magnetic resonance spectroscopy (1H NMR) among 3867 participants from the Multi-Ethnic Study of Atherosclerosis (MESA), with replication among 3569 participants from the Rotterdam and LOLIPOP studies...
May 18, 2019: European Heart Journal
#5
Karsten Keller, Lukas Hobohm, Matthias Ebner, Karl-Patrik Kresoja, Thomas Münzel, Stavros V Konstantinides, Mareike Lankeit
AIMS: Pulmonary embolism (PE) is the third most common cardiovascular cause of death; systemic thrombolysis is potentially lifesaving treatment in patients presenting with haemodynamic instability. We investigated trends in the use of systemic thrombolysis and the outcome of patients with acute PE. METHODS AND RESULTS: We analysed data on the characteristics, comorbidities, treatment, and in-hospital outcome of 885 806 PE patients in Germany between 2005 and 2015...
May 18, 2019: European Heart Journal
#6
Nicole E M Jaspers, Michael J Blaha, Kunihiro Matsushita, Yvonne T van der Schouw, Nicholas J Wareham, Kay-Tee Khaw, Marie H Geisel, Nils Lehmann, Raimund Erbel, Karl-Heinz Jöckel, Yolanda van der Graaf, W M Monique Verschuren, Jolanda M A Boer, Vijay Nambi, Frank L J Visseren, Jannick A N Dorresteijn
AIMS: The benefit an individual can expect from preventive therapy varies based on risk-factor burden, competing risks, and treatment duration. We developed and validated the LIFEtime-perspective CardioVascular Disease (LIFE-CVD) model for the estimation of individual-level 10 years and lifetime treatment-effects of cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. METHODS AND RESULTS: Model development was conducted in the Multi-Ethnic Study of Atherosclerosis (n = 6715) using clinical predictors...
May 18, 2019: European Heart Journal
#7
Taavi Tillmann
No abstract text is available yet for this article.
May 18, 2019: European Heart Journal
#8
Zerelda Esquer Garrigos, M Rizwan Sohail
No abstract text is available yet for this article.
May 17, 2019: European Heart Journal
#9
Russell J de Souza, Mahshid Dehghan, Sonia S Anand
No abstract text is available yet for this article.
May 16, 2019: European Heart Journal
#10
Sebastiano Gili, Victoria L Cammann, Susanne A Schlossbauer, Ken Kato, Fabrizio D'Ascenzo, Davide Di Vece, Stjepan Jurisic, Jozef Micek, Slayman Obeid, Beatrice Bacchi, Konrad A Szawan, Flurina Famos, Annahita Sarcon, Rena Levinson, Katharina J Ding, Burkhardt Seifert, Olivia Lenoir, Eduardo Bossone, Rodolfo Citro, Jennifer Franke, L Christian Napp, Milosz Jaguszewski, Michel Noutsias, Thomas Münzel, Maike Knorr, Susanne Heiner, Hugo A Katus, Christof Burgdorf, Heribert Schunkert, Holger Thiele, Johann Bauersachs, Carsten Tschöpe, Burkert M Pieske, Lawrence Rajan, Guido Michels, Roman Pfister, Alessandro Cuneo, Claudius Jacobshagen, Gerd Hasenfuß, Mahir Karakas, Wolfgang Koenig, Wolfgang Rottbauer, Samir M Said, Ruediger C Braun-Dullaeus, Adrian Banning, Florim Cuculi, Richard Kobza, Thomas A Fischer, Tuija Vasankari, K E Juhani Airaksinen, Grzegorz Opolski, Rafal Dworakowski, Philip MacCarthy, Christoph Kaiser, Stefan Osswald, Leonarda Galiuto, Filippo Crea, Wolfgang Dichtl, Klaus Empen, Stephan B Felix, Clément Delmas, Olivier Lairez, Ibrahim El-Battrawy, Ibrahim Akin, Martin Borggrefe, Ekaterina Gilyarova, Alexandra Shilova, Mikhail Gilyarov, John D Horowitz, Martin Kozel, Petr Tousek, Petr Widimský, David E Winchester, Christian Ukena, Fiorenzo Gaita, Carlo Di Mario, Manfred B Wischnewsky, Jeroen J Bax, Abhiram Prasad, Michael Böhm, Frank Ruschitzka, Thomas F Lüscher, Jelena R Ghadri, Christian Templin
AIMS: We aimed to evaluate the frequency, clinical features, and prognostic implications of cardiac arrest (CA) in takotsubo syndrome (TTS). METHODS AND RESULTS: We reviewed the records of patients with CA and known heart rhythm from the International Takotsubo Registry. The main outcomes were 60-day and 5-year mortality. In addition, predictors of mortality and predictors of CA during the acute TTS phase were assessed. Of 2098 patients, 103 patients with CA and known heart rhythm during CA were included...
May 16, 2019: European Heart Journal
#11
P J Devereaux, Wojciech Szczeklik
Myocardial injury after non-cardiac surgery (MINS) is due to myocardial ischaemia (i.e. supply-demand mismatch or thrombus) and is associated with an increased risk of mortality and major vascular complications at 30 days and up to 2 years after non-cardiac surgery. The diagnostic criteria for MINS includes an elevated post-operative troponin measurement judged as resulting from myocardial ischaemia (i.e. no evidence of a non-ischaemic aetiology), during or within 30 days after non-cardiac surgery, and without the requirement of an ischaemic feature (e...
May 16, 2019: European Heart Journal
#12
Leif Friberg, Tommy Andersson, Mårten Rosenqvist
AIMS: To investigate if patients with atrial fibrillation (AF) without clear indication for oral anticoagulant (OAC) due to perceived low stroke risk may benefit from OAC treatment when also dementia and intracerebral bleeding risks are considered. METHODS AND RESULTS: Retrospective study of cross-matched national registries of all individuals in Sweden with a hospital diagnosis of AF between 2006 and 2014 (n = 456 960). Exclusion was made of patients with a baseline CHA2DS2-VASc score >1, not counting female sex, and of patients with previous diagnosis of dementia or intracranial bleeding...
May 16, 2019: European Heart Journal
#13
David A Morrow, Eric J Velazquez, Adam D DeVore, Margaret F Prescott, Carol I Duffy, Yared Gurmu, Kevin McCague, Ricardo Rocha, Eugene Braunwald
AIMS: Circulating high-sensitivity cardiac troponin (hsTn) and soluble ST2 (sST2) reflect myocardial stress in patients with heart failure (HF). Production of cyclic guanosine 3'5' monophosphate (cGMP) in response to activation of natriuretic peptide receptors reduces cardiac afterload and preload. We assessed the effects of sacubitril/valsartan on these biomarkers in patients with reduced ejection fraction and acute decompensated HF (ADHF). METHODS AND RESULTS: PIONEER-HF was a randomized, double-blind trial of sacubitril/valsartan vs...
May 15, 2019: European Heart Journal
#14
Arman Qamar, Peter Libby, Deepak L Bhatt
No abstract text is available yet for this article.
May 15, 2019: European Heart Journal
#15
Shabbar Jamaly, Lena Carlsson, Markku Peltonen, Peter Jacobson, Kristjan Karason
AIMS: Obesity is associated with increased risk for heart failure. We analysed data from the Swedish Obese Subjects (SOS) study, a prospective matched cohort study, to investigate whether bariatric surgery reduces this risk. METHODS AND RESULTS: From the total SOS population (n = 4047), we identified 4033 obese individuals with no history of heart failure at baseline, of whom 2003 underwent bariatric surgery (surgery group) and 2030 received usual care (control group)...
May 14, 2019: European Heart Journal
#16
Annahita Sarcon, Jelena R Ghadri, Christian Templin
No abstract text is available yet for this article.
May 13, 2019: European Heart Journal
#17
Tinna Christersdottir, John Pirault, Anton Gisterå, Otto Bergman, Alessandro L Gallina, Roland Baumgartner, Anna M Lundberg, Per Eriksson, Zhong-Qun Yan, Gabrielle Paulsson-Berne, Göran K Hansson, Peder S Olofsson, Martin Halle
AIMS: Radiotherapy-induced cardiovascular disease is an emerging problem in a growing population of cancer survivors where traditional treatments, such as anti-platelet and lipid-lowering drugs, have limited benefits. The aim of the study was to investigate vascular inflammatory patterns in human cancer survivors, replicate the findings in an animal model, and evaluate whether interleukin-1 (IL-1) inhibition could be a potential treatment. METHODS AND RESULTS: Irradiated human arterial biopsies were collected during microvascular autologous free tissue transfer for cancer reconstruction and compared with non-irradiated arteries from the same patient...
May 12, 2019: European Heart Journal
#18
Milton Packer
The critical role of the left atrium (LA) in cardiovascular homoeostasis is mediated by its reservoir, conduit, systolic, and neurohormonal functions. Atrial fibrillation is generally a reflection of underlying disease of the LA, especially in patients with heart failure. Disease-related LA remodelling leads to a decline in both atrial contractility and distensibility along with an impairment in the control of neurohormonal systems that regulate intravascular volume. Catheter ablation can lead to further injury to the atrial myocardium, as evidenced by post-procedural troponin release and tissue oedema...
May 12, 2019: European Heart Journal
#19
Sergio Buccheri, Stefan James, Daniel Lindholm, Ole Fröbert, Göran K Olivecrona, Jonas Persson, Kristina Hambraeus, Nils Witt, David Erlinge, Oskar Angerås, Bo Lagerqvist, Giovanna Sarno
AIMS: Randomized clinical trials have consistently demonstrated the non-inferiority of bioabsorbable polymer drug-eluting stents (BP-DES) with respect to DES having permanent polymers (PP-DES). To date, the comparative performance of BP- and PP-DES in the real world has not been extensively investigated. METHODS AND RESULTS: From October 2011 to June 2016, we analysed the outcomes associated with newer generation DES use in Sweden. After stratification according to the type of DES received at the index procedure, a total of 16 504 and 79 106 stents were included in the BP- and PP-DES groups, respectively...
May 11, 2019: European Heart Journal
#20
Peter E Weeke, Jesper S Kellemann, Camilla Bang Jespersen, Juliane Theilade, Jørgen K Kanters, Michael Skov Hansen, Michael Christiansen, Peter Marstrand, Gunnar H Gislason, Christian Torp-Pedersen, Henning Bundgaard, Henrik K Jensen, Jacob Tfelt-Hansen
AIMS: It is Class I recommendation that congenital long QT syndrome (cLQTS) patients should avoid drugs that can cause torsades de pointes (TdP). We determined use of TdP risk drugs after cLQTS diagnosis and associated risk of ventricular arrhythmia and all-cause mortality. METHODS AND RESULTS: Congenital long QT syndrome patients (1995-2015) were identified from four inherited cardiac disease clinics in Denmark. Individual-level linkage of nation-wide registries was performed to determine TdP risk drugs usage (www...
May 11, 2019: European Heart Journal
Fetching more papers... 
